Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
Colorcon
Merck
Dow
Boehringer Ingelheim

Last Updated: November 13, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for AT9283

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug AT9283?

AT9283 is an investigational drug.

There have been 5 clinical trials for AT9283. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2010.

The most common disease conditions in clinical trials are Leukemia, Leukemia, Myeloid, Acute, and Neoplasms, Plasma Cell. The leading clinical trial sponsors are Cancer Research UK, NCIC Clinical Trials Group, and Astex Pharmaceuticals.

There are seven US patents protecting this investigational drug and forty-six international patents.

Recent Clinical Trials for AT9283
TitleSponsorPhase
AT9283 in Treating Young Patients With Relapsed or Refractory Acute LeukemiaCancer Research UKPhase 1
A Study of AT9283 in Patients With Relapsed or Refractory Multiple MyelomaNCIC Clinical Trials GroupPhase 2
AT9283 in Children and Adolescents With Relapsed and Refractory Solid TumorsCancer Research UKPhase 1

See all AT9283 clinical trials

Clinical Trial Summary for AT9283

Top disease conditions for AT9283
Top clinical trial sponsors for AT9283

See all AT9283 clinical trials

US Patents for AT9283

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AT9283   Start Trial Formylated N-heterocyclic derivatives as FGFR4 inhibitors NOVARTIS AG (Basel, CH)   Start Trial
AT9283   Start Trial Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases Astex Therapeutics Limited (Cambridge, GB)   Start Trial
AT9283   Start Trial Pharmaceutical compounds Astex Therapeutics Limited (Cambridge, GB)   Start Trial
AT9283   Start Trial Pharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyra- zol-4-yl]-urea Astex Therapeutics Limited (Cambridge, GB)   Start Trial
AT9283   Start Trial Methods and compositions relating to hematologic malignancies The Jackson Laboratory (Bar Harbor, ME)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AT9283

Drugname Country Document Number Estimated Expiration Related US Patent
AT9283 Australia 2016238436 2035-03-25   Start Trial
AT9283 Brazil 112017016817 2035-03-25   Start Trial
AT9283 Canada 2976766 2035-03-25   Start Trial
AT9283 China 107667092 2035-03-25   Start Trial
AT9283 European Patent Office 3274344 2035-03-25   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Mallinckrodt
Medtronic
McKinsey
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.